 The cost of clinical trials for orphan drugs is substantially lower than for other diseases —trial sizes are naturally much smaller than for more common diseases that affect more people.Small clinical trials and little competition place these orphan agents at an advantage when they come up for regulatory review.Further reduction to the cost of development is because of the tax incentives in the Orphan Drug Act of 1983.